SCYNEXIS (NASDAQ:SCYX) Earns Sell Rating from Analysts at StockNews.com

StockNews.com began coverage on shares of SCYNEXIS (NASDAQ:SCYX) in a research note issued to investors on Friday. The firm issued a sell rating on the stock.

SCYNEXIS Price Performance

Shares of NASDAQ:SCYX opened at $0.79 on Friday. The business’s fifty day moving average price is $0.95 and its two-hundred day moving average price is $1.08. SCYNEXIS has a fifty-two week low of $0.73 and a fifty-two week high of $3.07. The stock has a market capitalization of $30.79 million, a price-to-earnings ratio of -1.07 and a beta of 1.65.

SCYNEXIS (NASDAQ:SCYX) last posted its earnings results on Wednesday, May 14th. The company reported ($0.17) earnings per share for the quarter, topping the consensus estimate of ($0.23) by $0.06. The business had revenue of $0.26 million for the quarter, compared to analyst estimates of $0.14 million. SCYNEXIS had a negative net margin of 425.41% and a negative return on equity of 66.21%.

Institutional Inflows and Outflows

Institutional investors have recently modified their holdings of the company. Two Sigma Securities LLC acquired a new stake in SCYNEXIS during the 4th quarter valued at $25,000. Millennium Management LLC bought a new stake in shares of SCYNEXIS during the fourth quarter worth $31,000. Jane Street Group LLC acquired a new stake in shares of SCYNEXIS in the fourth quarter valued at $32,000. JPMorgan Chase & Co. acquired a new stake in shares of SCYNEXIS in the fourth quarter valued at $49,000. Finally, Squarepoint Ops LLC bought a new position in shares of SCYNEXIS in the fourth quarter valued at about $53,000. Institutional investors own 54.37% of the company’s stock.

SCYNEXIS Company Profile

SCYNEXIS, Inc, a biotechnology company, develops medicines to overcome and prevent difficult-to-treat and drug-resistant infections in the United States. It offers BREXAFEMME for the treatment of patients with vulvovaginal candidiasis (VVC) and recurrent VVC. The company's lead product candidate is Ibrexafungerp, an intravenous drug for the treatment of invasive candidiasis and/or candidemia, refractory invasive fungal infections, invasive aspergillosis, VVC, and recurrent VVC.